New drug delivery method shows potential for pancreatic cancer
A specific molecule targeting TROP2 helps deliver drugs to pancreatic cancer cells.
Researchers identified a way to deliver drugs to pancreatic ductal adenocarcinoma (PDAC). This method uses a high-affinity aptamer called T17 to target TROP2.
Scientists used protein-SELEX to find the T17 aptamer. They attached it to monomethyl auristatin E using an MC-Val-Cit-PAB linker to create T17-M.
An aptamer is a molecule that specifically binds to a target. T17-M undergoes clathrin-mediated internalization and lysosomal processing after binding to TROP2.
In animal models, T17-M suppressed tumor growth and reduced liver metastasis. It also induced immunogenic cell death by causing calreticulin exposure, ATP release, and HMGB1 secretion.
The treatment promoted dendritic-cell activation and CD8 + T cell infiltration. Combining T17-M with PD-1 blockade further enhanced tumor control and prolonged survival.
Key facts
- T17-M is an aptamer-drug conjugate that targets TROP2.
- T17-M suppressed tumor growth in cell-line-derived and patient-derived xenografts.
- Combining T17-M with PD-1 blockade helped prolong survival in immunocompetent models.